Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) and vTv Therapeutics (NASDAQ:VTVT – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, analyst recommendations, profitability and earnings.
Valuation & Earnings
This table compares Enanta Pharmaceuticals and vTv Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Enanta Pharmaceuticals | $65.32 million | 5.63 | -$81.89 million | ($2.41) | -5.24 |
| vTv Therapeutics | $36.84 million | 3.21 | -$26.97 million | ($1.06) | -28.30 |
Insider & Institutional Ownership
95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by company insiders. Comparatively, 6.0% of vTv Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of current recommendations for Enanta Pharmaceuticals and vTv Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Enanta Pharmaceuticals | 1 | 0 | 4 | 0 | 2.60 |
| vTv Therapeutics | 1 | 1 | 6 | 1 | 2.78 |
Enanta Pharmaceuticals presently has a consensus target price of $19.25, suggesting a potential upside of 52.29%. vTv Therapeutics has a consensus target price of $55.83, suggesting a potential upside of 86.11%. Given vTv Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe vTv Therapeutics is more favorable than Enanta Pharmaceuticals.
Volatility & Risk
Enanta Pharmaceuticals has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, vTv Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500.
Profitability
This table compares Enanta Pharmaceuticals and vTv Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Enanta Pharmaceuticals | -96.89% | -61.84% | -20.70% |
| vTv Therapeutics | N/A | -6.27% | -5.06% |
Summary
vTv Therapeutics beats Enanta Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
About vTv Therapeutics
vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
